← Back to screener

4D Molecular Therapeutics, Inc. FDMT

Rank #2217 · Nasdaq · $0.6B market cap
Audited by PricewaterhouseCoopers LLP, no going-concern flag in the latest filing.
Score
28.9
P/E
-3.7
P/B
1.92
ROE
-52.3%
Op. Margin
-507678.4%
Debt Ratio
16%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Weak

P/E -3.7x, P/B 1.92x. Ranks in the top 63% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -52.3%. Ranks in the top 94% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 16%. Ranks in the top 12% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 99.8% year over year. Ranks in the top 100% of the universe.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2020$0.0B$-0.1B$-0.0B$-0.0B-726.7-102
2021$0.0B$-0.1B$-0.1B$-0.1B-416.3-44
2022$0.0B$-0.1B$-0.1B$0.3B-395.513
2023$0.0B$-0.1B$-0.1B$0.3B-3516.510
2024$0.0B$-0.1B$-0.1B$0.2B-544.614
2025$0.0B$-0.2B$-0.2B$0.3B-507678.416

← See the full screener